by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

FairyGene, Inc. Warning Letter Details

Warning Letter

FairyGene, Inc.

FairyGene, Inc., 2 Pearl Buck Court, Suite 1 Bristol , PA 19007 United States

Issue DateJuly 31, 2026

FEI Number3023594691

Violations5

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated

FairyGene, Inc. FDA Warning Letter, July 31, 2026